Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > COMMENTARY
COMMENTARY
- Drug Companies Have No Time to Lose under New Pricing System
March 29, 2010
- Wholesalers, Pharmacy Chains to Ally to Improve Their Business
March 22, 2010
- New Pricing System Gives Makers Good Chance to Break from Old Business Practices
March 8, 2010
- Transfer Limited Financial Resources to Parties Who Make Effort to Provide Better Services
March 1, 2010
- Korosho Moves to Change Its Vaccine Policy
February 22, 2010
- Prospects of the Japanese Pharmaceutical Industry in 2010
February 15, 2010
- Number of Entrants into Market for Biosimilars Increases, But Barriers Are Still High
February 8, 2010
- New Pricing System to Make e-Detailing More Important
February 1, 2010
- Number of Holders of Designated Disease Treatment Beneficiary Certificate Up to 647,604
November 30, 2009
- Verify Acceptability of Prices before Revising Pricing Rule
November 30, 2009
- Pharmacology of Aging and Longevity: Looking for Anti-Aging Therapeutics （２）
November 2, 2009
- Pharmacology of Aging and Longevity: Looking for Anti-Aging Therapeutics （１）
November 2, 2009
- How Not to License a Drug into Japan
October 12, 2009
- TOPICS／Abbott Named One of the "Best Places to Launch a Career" by BusinessWeek
October 5, 2009
- NHI Drug Pricing System Reform Becomes Further Unpredictable Following Gov't Change
October 5, 2009
- COMMENTARY／Pharma Industry Watches New DPJ Administration with Both Anticipation and Concerns
September 21, 2009
- COMMENTARY／Will It Be Possible to Eliminate Use of Multiple Antipsychotics in Massive Doses?
September 14, 2009
- COMMENTARY／Establish Solid Criteria for Switching Ethical Drugs to OTC Status
September 14, 2009
- COMMENTARY／Korosho to Embark on Japanese Version of Sentinel Initiative
September 7, 2009
- COMMENTARY／Wholesalers Need to Analyze Causes of Their Failure
August 24, 2009
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…